AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05549037
Drug: Pembrolizumab, Sintilimab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.
Trial: NCT06096259
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
Trial: NCT05515627
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
Trial: NCT04924413
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
Trial: NCT05519293
Drug: H002
RxNorm normalized name: Hydrocodone Bitartrate
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule, Capsule
Trial: NCT05610189
Drug: Tavapadon
RxNorm normalized name: Tavapadon
DrugBank: Tavapadon (DB14899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00002165
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05536440
Drug: PF-07261271
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV or SC
Trial: NCT06566508
Drug: Leddermix Intracanal medication
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leddermix Intracanal medication
Trial: NCT06566508
Drug: Asiaticoside Intracanal medication
RxNorm normalized name: asiaticoside
DrugBank: Asiaticoside (DB14081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asiaticoside Intracanal medication
Trial: NCT05462756
Drug: Insulin Efsitora Alfa
RxNorm normalized name: Insulin efsitora alfa
DrugBank: Insulin efsitora alfa (DB19013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05462756
Drug: Insulin Lispro (U100)
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT05462756
Drug: Insulin Glargine (U100)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT05424432
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
Trial: NCT05424432
Drug: Neoadjuvant Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
Trial: NCT04842448
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
Trial: NCT05830123
Drug: HS-20093
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Trial: NCT05846451
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate-release oral tablet, 10 mg
Trial: NCT06565650
Drug: Miebo
RxNorm normalized name: Miebo
DrugBank: Perfluorohexyloctane (DB17823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% perfluorohexyloctane
Trial: NCT06565650
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6% sodium chloride solution
Trial: NCT05778227
Drug: Etidronic acid /sodium hypochlorite
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
Trial: NCT04678479
Drug: Ganaxolone
RxNorm normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ganaxolone
Trial: NCT00005779
Drug: Interleukin-12
RxNorm normalized name: interleukin-12
DrugBank: Edodekin alfa (DB15631)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04911127
Drug: 200mg Cannabidiol by capsules twice daily
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200mg twice daily via 50mg capsules
Trial: NCT04911127
Drug: 400mg Cannabidiol by capsules twice daily
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400mg twice daily via 50mg capsules
Trial: NCT04918147
Drug: elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
Trial: NCT04918147
Drug: placebo for elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The placebo for elotuzumab is 0.9% sterile normal saline for injection.
Trial: NCT04918147
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Trial: NCT04918147
Drug: diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Trial: NCT04918147
Drug: famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Trial: NCT04918147
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
Trial: NCT06234605
Drug: HC-7366
RxNorm normalized name: Casporyn HC
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
Trial: NCT05534620
Drug: Treosulfan
RxNorm normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT05534620
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06234605
Drug: Belzutifan
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan is a potent and selective HIF-2α inhibitor
Trial: NCT03544606
Drug: isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
Trial: NCT06641089
Drug: Sonelokimab
RxNorm normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonelokimab
Trial: NCT06641089
Drug: Risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active comparator
Trial: NCT05159128
Drug: JNJ-75105186
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-75105186 will be administered orally in Part 1 and 2.
Trial: NCT06105671
Drug: Symbicort
RxNorm normalized name: Symbicort
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants are administered 54 μg Formoterol and 1920 μg Budesonide
Trial: NCT06105671
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants are administered 54 μg Formoterol from an inhaler device
Trial: NCT06105671
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants are administered 120 μg Formoterol in a capsule, which is taken orally
Trial: NCT06105671
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are administered 600 mg Bronchitol
Trial: NCT05576974
Drug: Pegsitacianine
RxNorm normalized name: Pegsitacianine
DrugBank: Pegsitacianine (DB19098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
Trial: NCT05265273
Drug: Nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab will be administered as an IV infusion.
Trial: NCT06640361
Drug: Olverembatinib
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration with meal, QOD, every 28 days for a cycle.
Trial: NCT04747431
Drug: PBFT02
RxNorm normalized name: PBFT02
DrugBank: PBFT02 (DB18580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBFT02
Trial: NCT05014282
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be provided with a 10-week supply of nicotine patches
Trial: NCT05014282
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be provided with a 10-week supply of nicotine lozenges
Trial: NCT05052879
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
Trial: NCT04545866
Drug: surfactant (poractant alfa;Curosurf)
RxNorm normalized name: poractant alfa Intratracheal Suspension [Curosurf]
DrugBank: Recombinant surfactant protein D (DB18438)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
Trial: NCT05923541
Drug: RD13-02 cell infusion
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal CAR-T cells targeting CD7
Trial: NCT06235125
Drug: Cytalux
RxNorm normalized name: Cytalux
DrugBank: Pafolacianine (DB15413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Trial: NCT06518850
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
Trial: NCT05919680
Drug: NST-6179 Part A
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
Trial: NCT06381401
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: superficial cervical plexus block using 10 ml of bupivacaine 0.25%
Trial: NCT06381401
Drug: bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: superficial cervical plexus block using 10 ml of bupivacaine 0.125%
Trial: NCT05919680
Drug: NST-6179 Part B
RxNorm normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
Trial: NCT05249959
Drug: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Trial: NCT05675683
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receiving Capmatinib
Trial: NCT05327790
Drug: Lyophilized fecal microbiota (LFMT)
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vedolizumab or ustekinumab + FMT vs placebo
Trial: NCT00000754
Drug: Interferon alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000754
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000754
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05754749
Drug: Iohexol 350 Mg/mL Injectable Solution
RxNorm normalized name: iohexol 350 mg/mL injectable solution
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
Trial: NCT05651399
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
Trial: NCT05651399
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
Trial: NCT05166811
Drug: Magnesium Sulfate, Heptahydrate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
Trial: NCT00002066
Drug: Thymopentin
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06255730
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Trial: NCT05558007
Drug: Tadalafil 5mg
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral administration of tadalafil 5mg
Trial: NCT05558007
Drug: BZ371A
RxNorm normalized name: BZ371A
DrugBank: BZ371A (DB18101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
Trial: NCT04987944
Drug: Zavegepant
RxNorm normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg BID
Trial: NCT04906915
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The efficacy of ketamine was assessed by calculating oxygen supply and consumption
Trial: NCT06492954
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
Trial: NCT06380751
Drug: Saruparib (AZD5305)
RxNorm normalized name: Saruparib
DrugBank: Saruparib (DB18982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
Trial: NCT06380751
Drug: Camizestrant
RxNorm normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
Trial: NCT06380751
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4/6 Inhibitor
Trial: NCT06380751
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CDK4/6 Inhibitor
Trial: NCT06380751
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK 4/6 Inhibitor
Trial: NCT06380751
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Endocrine Therapy
Trial: NCT06380751
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endorcine Therapy
Trial: NCT06380751
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy
Trial: NCT06380751
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy
Trial: NCT05924672
Drug: Radium-223
RxNorm normalized name: Radium-223
DrugBank: Radium Ra-223 (DB12813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05924672
Drug: Technetium Tc 99M Medronate
RxNorm normalized name: technetium Tc 99m medronate
DrugBank: Technetium Tc-99m medronate (DB09138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undergo MDP